Loading stock data…
BAX
$16.62-0.59 (-3.43%)
Market ClosedLast close May 4
Baxter International Inc., through its subsidiaries, provides a portfolio of healthcare products in the United States.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Baxter International Inc. in the Healthcare sector is trading at $16.62. The stock is currently near its 52-week low of $15.73, remaining 19.4% below its 200-day moving average. Technical signals show neutral RSI of 41 and bearish MACD signal, explaining why BAX maintains its current current market pressure. The Whystock Score of 30/100 signals elevated caution as indicators diverge.
Ecosystem Influences
Neutral momentum (RSI 41) — price action in range
Long-term trend bearish (Price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Loading Financials...
Peer Comparison
JNJUNHPFE
Whystock Valuation Model
Whystock fair value is estimated using a trailing P/E model adjusted for return on equity: Fair P/E = 18 + (ROE × 20). Fair Value = (Current Price ÷ Trailing P/E) × Fair P/E. A base P/E of 18 represents a typical market multiple, scaled upward for companies that earn high returns on equity. The result is a theoretical "normalised" price — not a price target or investment advice. Large deviations are common for high-growth or loss-making companies.
Current Price$16.62
Potential Upside
5%
Whystock Fair Value$17.45
Price
UndervaluedFair ValueOvervalued
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Analyst Consensus13 analysts
Hold
Mean target$22.12+33.1%
Range$18.00 – $40.00
Fundamentals
Baxter International Inc., through its subsidiaries, provides a portfolio of healthcare products in the United States. The company operates through three segments: Medical Products & Therapies, Healthcare Systems & Technologies, and Pharmaceuticals. ...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$9.45B
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
Defensive asset. Lower volatility than the S&P 500.
0.62
Div Yield
Strong income play. Yield provides a meaningful total return floor.
195.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-2.53%
Volume
Today's trading volume
7.42M
Recent News
Assessing Baxter International (BAX) Valuation After Earnings Beat And Reaffirmed Outlook
Baxter International (BAX) has drawn fresh attention after reporting first quarter 2026 results that topped Wall Street expectations on revenue and adjusted earnings, while reaffirming full year guidance despite a GAAP net loss. See our latest analysis for Baxter International. Despite the positive earnings surprise and reaffirmed outlook, Baxter’s 1 day share price return of a 2.1% decline and 7 day share price return of a 5.23% decline sit against a 1 year total shareholder return of a...
Baxter International (BAX) Is Down 5.2% After Q1 Loss But Turnaround Guidance Reaffirmed - What's Changed
Baxter International reported first-quarter 2026 results with sales of US$2,701 million, a net loss of US$15 million, and a diluted loss per share of US$0.03, while reaffirming full-year guidance for flat to 1% GAAP sales growth. Despite the GAAP loss, Baxter’s revenue and adjusted earnings surpassed analyst expectations, supported by stronger Advanced Surgery and Drug Compounding performance and ongoing turnaround and efficiency initiatives. We’ll now examine how Baxter’s earnings beat and...
BAX Q1 Deep Dive: Turnaround Progress Amid Margin Pressures and Product Launches
Healthcare company Baxter International (NYSE:BAX) reported Q1 CY2026 results exceeding the market’s revenue expectations, with sales up 2.9% year on year to $2.70 billion. Its non-GAAP profit of $0.36 per share was 15.9% above analysts’ consensus estimates.
Baxter (BAX) Q1 2026 Earnings Call Transcript
Joining me today are Andrew Hider, President and Chief Executive Officer; and Anita Zielinski, Interim Chief Financial Officer, Chief Accounting Officer and Controller. During the call, we will be making forward-looking statements, including comments regarding our reiterated financial outlook for the full year 2026 and the anticipated drivers of the second quarter and second half 2026 performance.
Evercore Cuts Baxter (BAX) Price Target, Keeps Outperform Rating
Baxter International (NYSE:BAX) is one of the 10 Best Medical Stocks to Buy Under $30. On April 6, Evercore ISI analyst Vijay Kumar reduced the firm’s price target on Baxter International (NYSE:BAX) from $23 to $22 while maintaining an Outperform rating on the stock. This comes as part of the firm’s first-quarter preview of the […]